Paris

• Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2022-502238-22-00 5 2024-05-14 Ulcerative Colitis
• A trial to find out how safe REGN7075 is and how well it works in combination with cemiplimab for participants with advanced cancers Ended recruitment
  2022-501234-37-00 7 2024-05-07 Solid Tumours
• A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Ended recruitment
  2023-506669-70-00 5 2024-04-30 Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
• A clinical study of people with HIV-1 who have not taken antiretroviral therapy, one group will start treatment with a combination of doravi … Ended recruitment
  2022-502099-22-01 5 2024-04-29 HIV-1 Infection
• A clinical study of V940 treatment and pembrolizumab in people with bladder cancer (V940-005) Ended recruitment
  2023-505658-17-00 4 2024-04-16 Muscle-invasive Urothelial Carcinoma
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit … Ended recruitment
  2023-505928-59-00 5 2024-04-15 Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
• An Open-label Dosimetry, Tolerability and Safety Study of lutetium (177Lu) vipivotide tetraxetan in Patients with Progressive PSMA-Positive … Ended recruitment
  2023-503925-20-00 4 2024-04-04 Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Can
• TocilizuMab discontinuAtion in GIant Cell Arteritis Ended recruitment
  2023-505515-21-00 5 2024-04-02 Giant Cell Arteritis
• A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheim … Ended recruitment
  2023-506183-13-00 4 2024-03-29 Alzheimer’s Disease
• Tiragolumab and atezolizumab associated with chemotherapy in triple negative breast cancer Ended recruitment
  2022-501561-51-00 4 2024-03-27 Early and metastatic triple negative breast cancer
• A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either … Ended recruitment
  2023-503357-35-00 4 2024-03-20 Non-small Cell Lung Cancer (NSCLC)
• Randomized open-label Phase 2 trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adver … Ended recruitment
  2023-505863-35-00 4 2024-03-20 EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
• A Study of Mirikizumab (LY3074828) in Pediatric Participants with Crohn’s Disease (AMAY) Ended recruitment
  2024-511472-32-00 5 2024-03-12 Crohn's Disease
• MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended recruitment
  2023-504816-14-00 5 2024-03-08 Endometrial cancer
• Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease Ended recruitment
  2023-504471-25-00 5 2024-03-01 Fibrotic Lung Disease
• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal- … Ended recruitment
  2022-502446-27-00 5 2024-02-26 Relapsed or Refractory Myeloma
• PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed … Ended recruitment
  2023-505972-32-00 5 2024-02-26 locally advanced anal squamous cell carcinoma
• A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended recruitment
  2023-503827-25-01 5 2024-02-16 Non-Small Cell Lung Cancer (NSCLC)
• ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function (Varvara) Ended recruitment
  2022-503091-89-00 4 2024-02-15 Delayed graft function
• A study to evaluate the efficacy, safety, and tolerability of using an oral once-daily 2 drug regimen compared to an oral once-daily 3 drug … Ended recruitment
  2023-504993-40-00 5 2024-02-14 Human immunodeficiency virus (HIV)
• An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan … Ended recruitment
  2022-503040-41-00 4 2024-02-09 PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)
• A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression Ended recruitment
  2023-505268-12-00 5 2024-02-09 Treatment-resistant depression
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study of RZ358 in Patients with Congenital Hyperin … Ended recruitment
  2023-503240-13-00 5 2024-01-30 Hypoglycemia associated with congenital hyperinsulinism
• A Trial of Lu AG13909 in Participants with Congenital Adrenal Hyperplasia Ended recruitment
  2023-503711-15-00 7 2024-01-25 Congenital adrenal hyperplasia

Showing 1,393–1,416 of 2,286 trials